Future treatment approaches to multiple sclerosis

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 563-577

  Derwenskus, Joy ^a   Lublin, Fred D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

Alemtuzumab; Daclizumab; Emerging therapies; Estriol; Laquinimod; Ocrelizumab; Statins; Stem cell transplantation; Vitamin D

Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; DACLIZUMAB; ESTRIOL; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR; LAQUINIMOD; OCRELIZUMAB; VITAMIN D;

ANIMAL; ARTICLE; EMERGING THERAPIES; HUMAN; IMMUNOLOGY; METABOLISM; MULTIPLE SCLEROSIS; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ALEMTUZUMAB; DACLIZUMAB; EMERGING THERAPIES; ESTRIOL; LAQUINIMOD; OCRELIZUMAB; STATINS; STEM CELL TRANSPLANTATION; VITAMIN D;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HORMONES; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 84893475629     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00024-8     Document Type: Chapter

References (61)

1. Ali E.N., Healy B.C., Stazzone L.A., et al. Daclizumab in treatment of multiple sclerosis patients. Mult Scler 2009, 15:272-274.
2. Bar-Or A., Calabresi P.A., Arnold D., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008, 63:395-400.
3. Bebo B.F., Fyfe-Johnson A., Adlard K., et al. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 2001, 166:2080-2089.
4. Bielekova B., Richert N., Howard T., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc Natl Acad Sci 2004, 101:8705-8708.
5. Bielekova B., Howard T., Packer A.N., et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009, 66:483-489.
6. Birnbaum G., Cree B., Altafullah I., et al. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008, 71:1390-1395.
7. Brunmark C., Runstrom A., Ohlsson L., et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses in experimental autoimmune encephalomyelitis. J Neuroimmunol 2002, 130:163-172.
8. Burt R.K., Loh Y., Cohen B., et al. Autologous non-myeloablative hemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009, 8:244-253.
9. Burton J.M., Kimball S., Vieth R., et al. A phase I/II dose escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis. Neurology 2008, 70(supp1):A105.
10. CAMMS223 Trial Investigators Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
11. Chen J.T., Collins D.L., Atkins H.L., et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006, 66:1935-1937.
12. Cohen J.A. Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci 2013, 333:43-49.
13. Cohen J.A., Coles A.J., Arnold D.L., et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380:1819-1828.
14. Coles A.J., Wing M., Smith S., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999, 354:1691-1695.
15. Coles A., Deans J., Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004, 106:270-274.
16. Coles A.J., Fox E., Vladic A., et al. Alemtuzumab more effective than interferon-1a at 5-year follow-up of the CAMMS 223 Clinical Trial. Neurology 2012, 78:1069-1078.
17. Coles A.J., Twyman C.I., Arnold D.I., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
18. Comi G., Rovaris M., Abramsky O., et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092.
19. Comi G., Jeffery D., Kappos L., et al. Placebo-controlled trial or oral laquinimod for multiple sclerosis. N Engl J Med 2012, 366:1000-1009.
20. Confavreux C., Hutchinson M., Hours M.M., et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998, 339:285-291.
21. Connick P., Lolappan M., Crawley C., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11:150-156.
22. Cree B., Lamb S., Morgan K., et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
23. Fassas A., Anagnostopoulos A., Kazis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997, 20:631-638.
24. Fassas A., Kimiskidis V.K., Sakellari I., et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011, 76:1066-1070.
25. Gold R., Giovannoni G., Selmaj K., et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013, 381:2167-2175.
26. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
27. Hawker K., O'Connor P., Freedman M., et al. Efficacy and safety of rituximab in patients with primary progressive MS: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 72(Suppl 3):A254.
28. Jacob A., Weinshenker B.G., Violich I., et al. Treatment of neuromyelitis optica with rituximab retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
29. Jansson L., Olsson T., Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol 1994, 53:203-207.
30. Kamm C.P., El-Koussy M., Humpert S., et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. J Neurol 2012, 259:2401-2413.
31. Kappos L., Li D., Calabresi P., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebeo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
32. Karussis D., Karageorgiou C., Vaknin-Dembinsky A., et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67:1187-1194.
33. Kassis I., Vaknin-Dembinsky A., Karussis D. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther 2013, 6:63-68.
34. Kim S., Liva S.M., Dalal M.A., et al. Estriol ameliorates autoimmune demyelinating disease implications for multiple sclerosis. Neurology 1999, 52:1230-1238.
35. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
36. Kragt J.J., van Amerongen B.M., Killestein J., et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009, 15:9-15.
37. Markovic-Plese S., Jewwells V., Speer D. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2009, 72:1965.
38. Martinelli V., Costa G.D., Colombo B., et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scleros J 2013, 1-9.
39. McFarland H.F. The B cell - old player, new position on the team. N Engl J Med 2008, 358:664-665.
40. Munger K.L., Zhang S.M., O'Reilly E., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
41. Munger K.L., Levin L.I., Hollis B.W., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
42. Neuhaus O., Hartung H.P. Evaluation of atrovastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother 2007, 7:547-556.
43. Polman C., Barkhof F., Sandberg-Wollheim M., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005, 64:987-991.
44. Rastetter W., Molina A., White C.A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004, 55:477-503.
45. Rose J.W., Watt H.E., White A.T., et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004, 56:864-867.
46. Rose J.W., Burns J.B., Bjorklund J., et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis MRI and clinical results. Neurology 2007, 69:785-789.
47. Rudick R.A., Pace A., Rani M.R.S., et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009, 72:1989-1993.
48. Runia T.F., Hop W.C.J., de Rijke Y.B., et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012, 79:261-266.
49. Runstrom A., Leanderson T., Ohlsson L., et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice. J Neuroimmunol 2006, 173:6978.
50. Sicotte N.L., Liva S.M., Klutch R., et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002, 52:421-428.
51. Smolders J., Damoiseaux J., Menheere P., et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008, 194:7-17.
52. Soilu-Hanninen M., Aivo J., Lindstrom B.M., et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012, 83:565-571.
53. Soldan S.S., Alvarez Retuerto A.I., Sicotte N.L., et al. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 2003, 171:6267-6274.
54. Sorensen P.S., Lycke J.N., Eralinna J.P., et al. Simvastatin as add-on therapy to interferon beta 1-a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled ransomised phase 4 trial. Lancet Neurol 2011, 10:691-701. SIMCOMBIN study investigators.
55. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608.
56. Vollmer T.L., Soelberg Sorenson P., Arnold D.L., et al. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis 2011.
57. Waubant E., Pelletier D., Mass M., et al. Atorvastatin therapy in patients with clinically isolated syndrome and high-risk for conversion to multiple sclerosis: the STAyCIS study. Mult Scler 2009, 15:S272.
58. 3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76:1294-1296.
59. Wynn D., Kaufman M., Montalban X., et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010, 9:381-390.
60. Yamout B., Hourani R., Salti H., et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 2010, 227:185-189.
61. Yang J.S., Xu L.Y., Xio B.G., et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J Neuroimmunol 2004, 156:3-9.